Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Cytopenias after axi-cel in R/R large B-cell lymphoma: clinical implications

Paolo Strati, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the clinical implications of cytopenias 30 days or more after axicabtagene ciloleucel therapy in relapsed/refractory large B-cell lymphoma. He emphasizes the need for viral prophylaxis and monitoring of CD4+ cell counts. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.